#United States #DCISionRT #PreludeDx #Laguna Hills #Hannah Storm

Hannah Storm Partners with PreludeDx for Awareness on DCIS

Hannah Storm, a prominent and respected figure in sports broadcasting, recently entered a partnership with PreludeDx, a leader in precision diagnostics for early-stage breast cancer, to raise awareness about the importance of informed decision-making in breast cancer treatment. Having faced a personal battle with ductal carcinoma in situ (DCIS), a form of stage 0 breast cancer, she utilizes her platform to educate other women on the significance of early detection and personalized treatments.

In early 2024, Hannah was diagnosed with DCIS, going through the typical anxieties and uncertainties that accompany a cancer diagnosis. Her medical team recommended the DCISionRT test, a groundbreaking risk assessment tool that helps predict the potential benefits of radiation therapy specifically for DCIS patients. Storm's results revealed a low risk of recurrence within the next ten years and indicated that additional radiation would not contribute meaningfully to her treatment plan.

"The DCISionRT test was truly foundational to my treatment plan," Storm noted. She expressed gratitude that her results allowed her to skip radiation therapy altogether, easing her stress and anxiety significantly. This medico-scientific clarity was crucial for her emotional well-being during a challenging period.

The collaboration with PreludeDx aims to inform and empower other patients, helping them navigate their own treatment paths with confidence. Hannah Storm plans to advocate for the DCISionRT test, encouraging fellow patients to discuss this option with their healthcare providers. This initiative is not merely about the test itself but about fostering a deeper understanding of individual risk factors and the nuances of tailored treatment.

Dan Forche, CEO of PreludeDx, expressed enthusiasm for their partnership: "Hannah’s commitment to enhancing awareness of women's health aligns perfectly with our mission. Her advocacy as a breast cancer survivor adds weight to our efforts to personalize patient care through precision diagnostics."

Hannah has used her recognition and storytelling abilities to broaden the discussion surrounding breast cancer. Recently, she honored for her impactful contributions to sports broadcasting and philanthropy, notably at the Legends for Charity event benefiting St. Jude Children's Research Hospital, which further cements her position as a role model in health advocacy and education.

DCIS presents unique challenges in determining the optimal treatment path, as it accounts for around 20% of newly diagnosed breast cancer cases annually. Traditionally, decisions have leaned heavily on clinical assessments and historical protocols, leading to concerns about both overtreatment and undertreatment. With innovations like DCISionRT, patients can receive a more nuanced understanding of their individual situations, fostering a culture of informed consent where patients are equipped with the knowledge to make empowered medical decisions.

The DCISionRT assessment method combines tumor biology with multiple pathological risk factors to provide a comprehensive overview of a patient’s unique cancer scenario. It generates a Decision Score™ indicating the likelihood of recurrence after surgery, representing a leap forward in personalized cancer care. Unlike prior risk assessment tools, DCISionRT incorporates data from various biomarkers and clinical factors to refine the prognostic information provided.

PreludeDx has made it their mission to democratize access to such advanced diagnostic testing, ensuring that all women, regardless of their economic conditions or geographical locations, can benefit from innovations like this. Hannah Storm is committed to using her influence on social media and other platforms to enhance education about early detection and the importance of personalized treatment strategies.

Through this partnership, it's hoped that more women will be inspired to take control of their breast health, armed with personalized data that can guide their treatment options. In an era when tailored medicine is becoming increasingly feasible, the collaboration between Hannah Storm and PreludeDx could be critical in shaping the future of breast cancer care for many women navigating similar circumstances.

About PreludeDx

PreludeDx is at the forefront of breast cancer diagnostics, motivated by the objective of improving patient outcomes through advanced personalized technologies. Their work emphasizes the importance of solidifying patient-physician partnerships and understanding individual risks in a meaningful way. To learn more about their initiatives, visit their website or follow them on social media.